BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
price target on Travere Therapeutics to $43 from $47, while keeping a Buy rating. Following a three-month extension of the FDA's review for Filspari's use in FSGS, the new PDUFA action date has been moved to April 13 this year. While the firm acknowledges the delay as a temporary setback, the overall outlook for approval remains positive, given that the extension allows for a deeper evaluation of the clinical data rather than indicating a fundamental issue with the drug's safety or manufacturing. On January 13, Travere Therapeutics announced that the US FDA extended the review period for its supplemental New Drug Application/sNDA for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis/FSGS. The new Prescription Drug User Fee Act target action date is now set for April 13 this year. The extension was triggered by Travere's recent submission of additional data requested by the FDA to further define the clinical benefit of the drug. The agency classified the
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) had its "neutral" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech SummitBusiness Wire
- Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative? [Yahoo! Finance]Yahoo! Finance
- TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law FirmGlobeNewswire
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 2/9/26 - Form SCHEDULE
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- TVTX's page on the SEC website